Profile data is unavailable for this security.
About the company
BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.
- Revenue in USD (TTM)377.00k
- Net income in USD-6.17m
- Incorporated2022
- Employees11.00
- LocationBioRestorative Therapies Inc40 MARCUS DRIVEMELVILLE 11747United StatesUSA
- Phone+1 (631) 760-8100
- Websitehttps://www.biorestorative.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yubo International Biotech Ltd | 25.78k | -2.00m | 9.71m | 18.00 | -- | -- | -- | 376.47 | -0.0167 | -0.0167 | 0.0002 | -0.0261 | 0.0145 | 0.0467 | 0.1935 | 1,432.22 | -120.65 | -- | -- | -- | 80.41 | -- | -8,325.41 | -- | 0.1598 | -17,544.82 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -70.87m | 9.71m | 48.00 | -- | 0.608 | -- | -- | -15.59 | -15.60 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -74.80 | -- | -83.22 | -- | -- | -- | -- | -- | -- | -- | 0.0064 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
| BioCardia Inc | 71.00k | -7.72m | 9.79m | 16.00 | -- | 3.51 | -- | 137.85 | -4.22 | -4.22 | 0.036 | 0.6086 | 0.0142 | -- | 1.25 | 4,437.50 | -154.22 | -107.34 | -401.77 | -154.17 | -- | -- | -10,876.06 | -1,779.24 | -- | -- | 0.00 | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| Kiora Pharmaceuticals Inc | 16.02m | 5.55m | 9.93m | 12.00 | 5.41 | 0.3308 | 1.78 | 0.62 | -0.5993 | -0.5993 | 4.89 | 10.01 | 0.5889 | -- | 9.18 | 1,335,000.00 | 20.40 | -70.52 | 22.75 | -81.86 | -- | -- | 34.64 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| BioRestorative Therapies Inc | 377.00k | -6.17m | 10.00m | 11.00 | -- | 1.00 | -- | 26.52 | -0.7135 | -0.7135 | 0.0546 | 1.44 | 0.0266 | -- | 3.69 | 34,272.73 | -43.49 | -192.11 | -53.99 | -329.32 | 79.04 | -- | -1,636.79 | -19,116.15 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 43.67 | -- | 67.77 | -- |
| Imunon Inc | 0.00 | -19.45m | 10.05m | 33.00 | -- | 1.23 | -- | -- | -1.89 | -1.89 | 0.00 | 0.5649 | 0.00 | -- | -- | 0.00 | -99.63 | -50.18 | -137.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Vaccinex Inc | 388.00k | -18.58m | 10.06m | 37.00 | -- | -- | -- | 25.93 | -12.15 | -12.15 | 0.2512 | -0.5081 | 0.1047 | -- | 0.4046 | 10,486.49 | -501.27 | -262.29 | -- | -- | -- | -- | -4,787.89 | -4,257.17 | -- | -49.48 | -- | -- | 107.27 | -4.67 | -2.20 | -- | -22.20 | -- |
| Dominari Holdings Inc | 12.59m | -22.69m | 10.23m | 26.00 | -- | 0.2673 | -- | 0.8126 | -3.85 | -3.85 | 2.11 | 6.10 | 0.2361 | -- | 3.80 | 484,192.30 | -42.55 | -26.82 | -44.27 | -27.45 | -- | -- | -180.22 | -3,353.52 | -- | -4.83 | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Oncotelic Therapeutics Inc | 0.00 | -4.66m | 10.31m | 22.00 | -- | 1.17 | -- | -- | -0.0115 | -0.0115 | 0.00 | 0.0217 | 0.00 | -- | -- | 0.00 | -17.29 | -25.03 | -39.98 | -48.76 | -- | -- | -- | -1,692.93 | -- | -0.5009 | 0.614 | -- | -- | -- | -255.12 | -- | -- | -- |
| ELEVAI Labs Inc | 2.45m | -5.47m | 10.46m | 18.00 | -- | 0.1166 | -- | 4.27 | -0.2924 | -0.2924 | 0.1303 | 0.1733 | 0.3826 | 0.9499 | 216.67 | 135,897.80 | -85.53 | -- | -121.34 | -- | 71.15 | -- | -223.57 | -- | 3.40 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 10.46m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Indaptus Therapeutics Inc | 0.00 | -14.89m | 10.66m | 7.00 | -- | 1.77 | -- | -- | -1.72 | -1.72 | 0.00 | 0.5887 | 0.00 | -- | -- | 0.00 | -114.42 | -66.55 | -138.96 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
| Viaderma Inc | 17.80m | 2.31m | 10.73m | 75.00 | 0.0005 | 0.00003 | 1.98 | 0.603 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
| Turnstone Biologics Corp | 0.00 | -74.42m | 10.86m | 81.00 | -- | 0.2488 | -- | -- | -3.23 | -3.23 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -78.42 | -- | -91.27 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to BioRestorative Therapies Inc's reporting currency: US Dollar USD
13.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Auctus Fund Management LLCas of 30 Sep 2024 | 681.23k | 9.84% |
| Geode Capital Management LLCas of 30 Sep 2024 | 55.71k | 0.81% |
| StoneX Group, Inc. (Investment Management)as of 30 Sep 2024 | 50.10k | 0.72% |
| The Wealth Alliance LLC (New York)as of 30 Sep 2024 | 40.00k | 0.58% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 20.47k | 0.30% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 20.46k | 0.30% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 20.00k | 0.29% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 17.50k | 0.25% |
| US Financial Advisors LLCas of 30 Sep 2024 | 17.14k | 0.25% |
| G1 Execution Services LLCas of 30 Sep 2024 | 12.77k | 0.19% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
